Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mel66: Enhanced Melanoma Vaccine with CDX-1140
NCT04364230Phase 2Completed
- Start
- Sep 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CDX-1140 in melanoma and Uveal melanoma (UM). Primary endpoints: Safety of CDX-1140 + melanoma peptide vaccine + PolyICLC and Immune response rate to melanoma vaccine combined with CDX-1140 at Day 176. Started Sep 2020; status: completed.
02
Drugs
CDX-1140
03
Conditions
melanomaUveal melanoma (UM)
Beyond the preview
Go deeper on NCT04364230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364230.